Reboxetine in the treatment of depression in the elderly: Pilot study

Journal of Geriatric Psychiatry and Neurology

Volumn 12, Issue 4, 1999, Pages 206-210

  Andreoli, Vittorino ^a   Carbognin, Giorgio ^b   Abati, Alberto ^a   Vantini, Giovanni ^b  

^a Ospedale San Giovanii Battista   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DYSTHYMIA; ELECTROCARDIOGRAM; FEMALE; HUMAN; PRIORITY JOURNAL; RATING SCALE; TACHYCARDIA;

EID: 0033394717     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198879901200407     Document Type: Article

References (22)

1. NIH Consensus Development Panel on Depression in Late Life. Diagnosis and treatment of depression in late life. JAMA 1992; 268:1018-1024.
2. Dunner DL. An overview of paroxetine in the elderly. Gerontology 1994; 40(Suppl 1):21-27.
3. Volz H-P, Moller H-J. Antidepressant drug therapy in the elderly - a critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry 1994; 27:93-100.
4. Finch EJL, Ramsay R, Kanton CLE. Depression and physical illness in the elderly. Clin Geriatr Med 1992; 8:275-287.
5. Katona C. Rationalizing antidepressants for elderly people. Int Clin Psychopharmacol 1995; 10(Suppl 1):37-40.
6. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 94:5A-2S-5A-12S.
7. Tsujimoto G, Hashimoto K, Hoffman BB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age, Part 2. Int J Clin Pharmacol Ther Toxicol 1989; 27:102-116.
8. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153:311-320.
9. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11(4) (Suppl): S9-S15.
10. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11(4) (Suppl):S33-S37.
11. Dostert P, Benedetti MS, Poggesi I. Review of pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7(Suppl 1): S23-S35.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd Ed. Washington, DC: American Psychiatric Association, 1980.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd Ed. rev. Washington, DC: American Psychiatric Association, 1987.
14. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, 1976.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
16. Koenig HG, Meador KG, Cohen HJ, Blazer DG. Self-rated depression scales and screening for major depression in the older hospitalized patient with medical illness. J Am Geriatr Soc 1988; 36:699-706.
17. Ashford JJ, Rahman K. Fluvoxamine versus dothiepin: a double-blind study in elderly depressed patients [abstract]. J Psychopharmacol 1990; 4:299.
18. Katz IR, Simpson GM, Curlik SM, et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990; 51(Suppl 7):41-47.
19. Finkel SI. Efficacy and tolerability of antidepressant therapy in the old-old. J Clin Psychiatry 1996; 57(Suppl 5):23-28.
20. Halper JP, Mann JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry 1988; 153(Suppl 3):87-98.
21. Christensen DD. Rational antidepressant selection in the elderly. Geriatrics 1995; 50(Suppl 1):S41-S50.
22. Gareri P, Stilo G, Bevacqua I, et al. Antidepressant drugs in the elderly. Gen Pharmacol 1998; 30:465-475.